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HypothyroidismAbstract Aim of the work: This work aimed to determine the frequency of subclinical memory
dysfunction in a group of Malaysian systemic lupus erythematosus (SLE) patients and to study
its relation to clinical characteristics, laboratory investigations and disease activity.
Patients and methods: Fifteen SLE patients attending the Universiti Kebangsaan Malaysia Med-
ical Centre (UKMMC) and not known to have neuropsychiatric lupus were recruited. These
patients were assessed using the Wechsler Memory Scale. Disease activity was assessed using the
SLE disease activity index 2000 (SLEDAI-2K).
Results: The median age of the patients was 28 years (25–37 years) and they were 14 females and
one male. Their median disease duration was 9.3 years (4.8–10 years). Their median SLEDAI-2K
was 4 (0–6). Memory dysfunction was identified in 7/15 (46.7%) SLE patients and was significantly
associated with lower serum thyroxine levels (median 12.27; 11.8–13.3 lg/dl) (p= 0.027) compared
to those without memory impairment (15.48; 14.39–16.56 lg/dl). Auditory memory impairment was
associated with the education level as the auditory memory index was significantly lower in patients
with secondary education (n= 7, median 88; 86.5–91.5) compared to those who received tertiary
education (n= 8, median 103; 97.5–119.5) (p= 0.025) while visual memory was influenced by dis-
ease duration (p= 0.016). There was no association between overall memory dysfunction and dis-
ease duration, number of relapses, clinical manifestations and SLEDAI-2K scores.
190 M.S.M. Said et al.Conclusion: There is a high frequency of subclinical memory dysfunction among SLE patients. A
remarkable association is present with lower thyroxine. Auditory memory impairment is related to
the level of education and visual memory to disease duration.
 2015 The Authors. Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of
Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a systemic chronic
autoimmune disease that can affect all organs. The pathogen-
esis remains elusive and the etiology is multifactorial [1]. Sev-
eral factors as cytokine overproduction [2,3], oxidative stress
[4], matrix metalloproteinase [5] and apoptosis [6] play a con-
siderable role in the development of SLE. The kidney is com-
monly involved signifying the value of regular screening for
early and appropriate management [7]. Comorbidities as dys-
lipidemia and metabolic syndrome [8,9] could lead to func-
tional disability, impaired quality of life and significantly
affect disease activity and damage.
Neurological manifestations are common among SLE
patients and these are highly diverse and often have major
prognostic consequences. One of the most prevalent neuropsy-
chiatric SLE (NPSLE) manifestations is cognitive dysfunction
[10] reported to be as high as 81% [11], while compilation from
multiple databases showed that it ranged between 21% and
67% [12]. The most common cognitive impairment in SLE
patients is memory dysfunction [10,13]. Memory dysfunction
in SLE patients was found to be associated with multiple risk
factors including antiphospholipid antibodies, consistent corti-
costeroid use, diabetes, higher depression score and lower edu-
cation level [11]. A contribution of higher disease activity to the
development of memory impairment has been reported [12].
Memory functioning generally refers to the ability to retain
learned information over time and is one of several primary
domains of cognitive ability typically evaluated in the context
of a comprehensive neuropsychological assessment [14,15]. It
is important to note that memory is typically viewed as a group
of related abilities based on the duration of time that informa-
tion is retained (short vs. Long term) and the content that is
stored [15–17]. Furthermore, memory is also composed of mul-
tiple processes which include encoding, storage and retrieving
which are typically linear in progression. Any defect in any
of these steps will impair memory functioning and each of
these must be assessed in order to provide a comprehensive
understanding of a patient’s memory functioning [15,18].
The Wechsler Memory Scale (WMS) is a battery of subtests
frequently administered in a neuropsychological assessment
[19] and is designed to evaluate multiple aspects of learning
and memory. Since the first edition that was published in
1945 [20], it has been repeatedly revised and updated to the
current 4th edition (WMS-IV). Administration of this new edi-
tion in its entirety generates primary index scores for immedi-
ate and delayed memory as well as secondary indexes of visual
working memory, auditory memory and visual memory [21].
In the 4th edition, only three out of seven subtests were
retained from the previous version whereas the remaining four
tests are new. There are no data as regards this vital aspect in
our local SLE population. The aim of this study was to deter-
mine frequency of subclinical memory dysfunction in a groupof Malaysian SLE patients and to study its relation to clinical
characteristics, laboratory investigations and disease activity.
2. Patients and methods
This was a cross-sectional study which recruited SLE patients
from both the Rheumatology and Nephrology/SLE clinics at
the Universiti Kebangsaan Malaysia Medical Centre
(UKMMC) (Grant: FF-260-2012) and not known to have his-
tory of neuropsychiatric lupus. The SLE patients fulfilled the
American College of Rheumatology revised classification crite-
ria [10] and were >18 years old. An SLE disease activity
index-2000 (SLEDAI-2K) was calculated for the studied
patients [22]. All patients were administered the Wechsler
Memory Scale-4th edition UK version (WMS-IVUK) question-
naire [23] by the researcher. This study was approved by the
UKMMC Medical Research and Ethics Committee (MREC)
with the research code, FF-260-2012 and all the included
patients gave an informed consent.
The Wechsler Memory Scale-4th edition (WMS-IV) is an
individually administered battery of tests designed to assess
memory functioning in individuals aged 16–90 [23]. It is devel-
oped and published by Pearson Education Inc. It is organized
into five main memory index scores: auditory, visual, visual
working, immediate and delayed memory indices. These index
scores are scaled on a metric mean of 100 ± 15. An index score
of less than 90 in any main category is considered to be below
normal, and defined as memory impairment.
2.1. Statistical analysis
Demographic data of participants were recorded and charted
accordingly. Data were analyzed using SPSS version 20.0.
All numerical data were subjected to normality testing using
Kruskal–Wallis Analysis. Data were analyzed using non-
parametric tests and expressed as median with interquartile
range (IQR). For categorical data, chi-square with Yate’s cor-
rection was used and for non-categorical data, Mann–Whitney
U and Kruskal–Wallis tests were used. A p-value of 60.05 was
considered significant.
3. Results
Fifteen SLE patients with a median age of 28 years (25–
37 years), 14 females and 1 male with disease duration of
9.3 years (4.8–10 years) were included. The sociodemographic
data, level of education and comorbidities of the patients are
presented in Table 1.
There was no association between overall memory dysfunc-
tion and duration of SLE, number of relapses, number of
major systems involvement and SLEDAI-2K scores as shown
in Table 2. However, visual memory was influenced by disease
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of the memory impaired and non-impaired groups at the time
of the study are summarized in Table 3. However, the
memory-impaired group did have a significantly lower serum
thyroxine level (p= 0.027) albeit still within the normal range
and TSH levels were normal.
The majority of the patients were on prednisolone; memory
impaired group, 5/7 (71.4%) and non-impaired group, 7/8
(87.5%). Cumulative prednisolone dose was not different
between the two study groups. There was no association found
between memory dysfunction and the use of prednisolone.
Cumulative numbers of agents used were similar between the
two study groups.
The memory main sub-domain indices (auditory; visual,
immediate and delayed indices) of the studied patients are pre-
sented in Table 4. There were significant differences in 3 out ofTable 1 Sociodemographic data, level of education and co-morbid
Variable median (IQR) or n (%) SLE patients wi
All (n= 15)
Age (years) 28 (25–37)
Gender F:M (n) 14:1
Ethnicity Malay 10 (66.7)
Chinese 4 (26.6)
Indian 1 (6.7)
Education Secondary Lower 2 (13.4)
Upper 5 (33.5)
Tertiary 8 (53.6)
Co-morbidities Hypertension 8 (53.6)
Dyslipidemia 4 (26.8)
Diabetes 3 (20.1)
PVD 1 (6.7)
Smoking 0 (0)
Body mass index (BMI) 24.3 (21.5–32.1)
Blood pressure (mmHg)
Systole 130 (110–138)
Diastole 80 (80–85)
SLE: systemic lupus erythematosus, IQR: interquartile range, PVD: peri
Table 2 Clinical characteristics, disease duration and activity in SL
Clinical characteristic median (IQR) or n (%) SLE patients
All (n= 15)
Disease duration (years) 9.3 (4.8–10)
Activity Remission duration (m) 9 (3–20)
Relapses (n) 2 (1–3)
SLEDAI-2K 4 (0–6)
Worse SLEDAI-2K 17 (11–21)
Systems involved Musculoskeletal 11 (73.3)
Lupus nephritis 8 (53.3)
Hematological 7 (46.7)
Cutaneous 6 (40)
Vasculitis 3 (20)
Neurological 0 (0)
Cumulative number 4 (3–4)
SLE: systemic lupus erythematosus, IQR: interquartile range, SLEDAI-24 memory sub-domains between the memory impaired com-
pared to the non-impaired groups viz visual memory index
(VMI) (p= 0.004), immediate memory index (IMI)
(p= 0.009) and delayed memory index (DMI) (p= 0.012).
Only the auditory memory index was not affected. There was
a significant association between the auditory memory index
(AMI) and the level of education (Table 5). The other memory
sub-domains were not affected. There was association between
the memory indices sub-domain according to the number of
systems involved (Table 5).4. Discussion
Cognitive impairment is a well recognized feature of neuropsy-
chiatric manifestation in SLE [11]. One of the major compo-ities of SLE patients with and without memory impairment.
thout neuropsychiatric manifestations (n= 15)
Memory p
Non-impaired (n= 8) Impaired (n= 7)
28 (24.5–36) 30 (25–37) 0.77
8:0 6 :1 NA
3 (37.5) 7 (100) NA
4 (50) 0 (0)
1 (12.5) 0 (0)
1 (12.5) 1 (14.3) 0.37
2 (25) 3 (42.9)
5 (62.5) 3 (42.9)
4 (50) 4 (57.1) 1
3 (37.5) 1 (14.3) 0.57
2 (25.0) 1 (14.3) 1
1 (12.5) 0 (0) 1
0 (0) 0 (0) NA
23.9 (21.3–35) 26.8 (21.5–32) 1
125 (110–138) 130 (100–138) 1
83 (72–89) 80 (80–80) 0.26
pheral vascular disease, NA: not applicable.
E patients with and without memory impairment.
without neuropsychiatric manifestations (n= 15)
Memory p
Non-impaired (n= 8) Impaired (n= 7)
120 (109–138.2) 62 (46.5–96) 0.12
16.5 (4.5–38) 6 (2.5–10.5) 0.13
2 (0.5–3) 2 (1–2.5) 1
4 (2.5–7) 4 (0–8) 0.26
18 (10–24) 16 (11–21) 0.52
6 (75) 5 (71.5) 1
5 (62.5) 3 (42.9) 0.62
3 (37.5) 4 (57.1) 0.62
4 (50) 2 (28.6) 0.61
3 (37.5) 0 (0) 0.2
0 (0) 0 (0) NA
3.5 (3–4) 4 (3–5) 0.63
K: SLE disease activity index-2000, NA: not applicable.
Table 3 Laboratory parameters in SLE patients with and without memory impairment.
SLE patients without neuropsychiatric manifestations (n= 15)
Parameter median (IQR) Memory p
Non-impaired (n= 8) Impaired (n= 7)
Hb (g/dl) 12.5 (11.7–12.7) 12.4 (11.8–12.9) 0.95
WBC count (103/mm3) 8 (6.4–8.9) 7.7 (6.5–8.7) 0.86
Platelets (103/mm3) 255 (223–290) 284 (263–251) 0.13
Serum creatinine (mg/dl) 56 (49–64) 64 (55–108) 0.35
eGFR 118.2 (106.6–130.2) 95.8 (57.8–120.7) 0.3
Albumin (mg/dl) 43 (40.5–46) 43.5 (40.5–45) 0.77
ALT (IU/L) 11 (10–21) 22 (16–27) 0.2
ALP (IU/L) 57.5 (49–80.5) 65 (58.5–65.5) 0.95
Free T4 (lg/dl) 15.48 (14.39–16.6) 12.27 (11.8–13.3) 0.027
TSH 0.67 (0.53–0.73) 1 (0.54–1.51) 0.18
C3! (mg/dl) 53.3 (45.9–87.5) 80.5 (28.7–96.5) 0.42
C4! (mg/dl) 10.3 (5.9–17.3) 11 (5.0–15.4) 1
SLE: systemic lupus erythematosus, IQR: interquartile range, Hb: hemoglobin, WBC: white blood cell, eGFR: estimated glomerular filtration
rate, ALT: alanine transaminase, AST: aspartate transaminase, ALP: alkaline phosphatase, T4: thyroxine, TSH: thyroid stimulating hormone,
C: complement. !The lowest recorded serum C3 and C4 level during the relapse of SLE episodes. Bold value is significant at p< 0.05.
Table 4 Memory indices of the four main sub-domains in
SLE patients without neuropsychiatric lupus (n= 15).
Auditory
(AMI)
Immediate
(IMI)
Delayed
(DMI)
Median 101 100 104
Mode 95 100 93
Minimum 85 87 90
Maximum 128 123 133
Percentiles 25th 93 94 93
75th 115 109 114
SLE: systemic lupus erythematosus, AMI: auditory memory index,
VMI: visual memory index, IMI: immediate memory index, DMI:
delayed memory index.
192 M.S.M. Said et al.nents in the cognitive process is memory. Memory per se is an
integration of four major sub-domains i.e. auditory, visual,
immediate and delayed memory. Memory function requires
simultaneous multistep processes of these sub-domains and
any disruption of these steps may cause impairment of mem-
ory [24].Table 5 Memory indices according to the level of education
neuropsychiatric lupus.
Parameter median (IQR) Memory index (MI) in
Auditory (AMI)
Education Secondary (n= 7) 88 (86.5–91.5)
Tertiary (n= 8) 103 (97.5–119.5)
p 0.025
System involved 1–2 94 (88–100)
3–4 103 (95–115)
>5 95 (94–109.5)
p 0.44
SLE: systemic lupus erythematosus, IQR: interquartile range, AMI: au
memory index, DMI: delayed memory index. Bold value is significant atPrevious studies have focused on overall cognitive function
rather than the detailed components of memory [25,26]. The
prevalence of memory dysfunction in SLE was reported to
range from 43% to 75% [27]. A small simple-to-administer
memory assessment tool would be invaluable as regards the
detailed study of the subdomains. Hence we conducted this
pilot study using the newly updated WMS-IV memory assess-
ment tool. WMS-IV is known to be more comprehensive and
simple-to-use battery of memory tests [23]. The WMS-IV has
not been used among the lupus population, although it was
widely used in neuropsychological assessment [28]. There are
no reference ranges for the memory indices in our local SLE
population. The reported study is small and employed one
or more combinations of various neuropsychological batteries
of tests to assess overall cognitive function [20]. Using this
tool, a frequency of 46.7% memory dysfunction was found
in the Malaysian SLE population which is consistent with
other results [27].
There were no associations between memory dysfunction
with the age or level of education of the SLE patients. These
findings concur with those reported by Maneeton et al. and
Olazara´n et al. [29,30]. Of interest, the age and level ofand number of systems involved in SLE patients without
SLE patients without neuropsychiatric lupus (n= 15)
Visual (VMI) Immediate (IMI) Delayed (DMI)
95 (91–99.5) 94 (91.0–94) 94 (93.5–97)
101 (89.5–113.5) 104 (100–114) 107.5 (106.6–119.5)
0.56 0.06 0.17
95.5 (87–104) 97 (89–105) 100 (95–105)
101.0 (93–110) 110.0 (94–119) 106 (93–119)
90 (87.5–108) 103 (95–106) 107 (100–109)
0.69 0.7 0.85
ditory memory index, VMI: visual memory index, IMI: immediate
p< 0.05.
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rable to those of ours [30]. In contrast, Murray et al. reported
that a low education level was one of the predictors of memory
dysfunction in their SLE population [31] and significantly
associated with declining cognitive function [32]. Although
the overall memory function and education levels were not
associated in this study, auditory memory index (AMI) scores
were significantly lower in those with a lower education level
(p= 0.025). This was in agreement with the results of others
[30,33,34]. Thus auditory memory appears to be the earliest
memory sub-domain to be affected in SLE patients with lower
education levels.
Interestingly, serum thyroxine levels showed a significant
association with overall memory impairment in SLE.
Hypothyroidism has been associated with memory deficits
[35], although to date, there are no reported associations
between these two entities in SLE. Whether thyroxine supple-
mentation is indicated or useful in reversing this subtle mem-
ory dysfunction can only be speculative at present.
There were markedly lower scores in three of the four mem-
ory sub-domains. This involvement of multiple memory sub-
domains is consistent with those results of others [28].
Although these have focused on overall cognitive function
rather than memory dysfunction per se.
Disease duration, number of relapses, disease activity as
measured by SLEDAI-2K and cumulative number of systems
involvement did not show any association with the overall
memory performance in our patients. These findings are simi-
lar to those reported by others [36,37]. Data concerning mem-
ory dysfunction and SLE disease activity are highly
controversial. Others have concentrated on the overall cogni-
tive function in relation to SLE disease activity. Fisk et al.
reported an association between cognitive decline and higher
SLEDAI scores [38]. In contrast, Carbotte et al. found no rela-
tion [39]. Skeel et al. also found no decline in the memory
parameters of 17 SLE patients with cognitive complaints
[40]. However, all the above authors only measured the SLE-
DAI score at the time of study which will not reflect true past
disease activity whereas, we examined the current and worst
SLEDAI-2K scores during the course of illness. This should
have detected any past damage not hitherto recognized at
the time of active disease. We too found no association
between memory dysfunction and current or worst SLEDAI-
2K scores. All memory sub-domains were also not associated
with SLEDAI-2K.
It has been reported that the verbal (auditory) sub-domain
was the most affected by SLE [30,33,34]. Cumulative number
of system involvement, co-morbidities and number of
immunomodulatory medications used were comparable
between SLE patients with and without memory impairment.
Disease duration influenced the visual memory. This associa-
tion has not been previously reported in the literature. This
may represent the early subclinical phase of memory
dysfunction.
Corticosteroid dosage and cumulative dose did not impact
the memory indices in our study population. There are con-
flicting data in the literature concerning the association
between memory function and corticosteroid use. A strong
association between consistent steroid use and the cognitive
process has been reported [32]. Whereas others noted that only
the daily prednisolone dosage affected cognitive function [29].
However other studies also failed to demonstrate any relationbetween steroid use and memory dysfunction [37,39]. The
underlying damage of the subtle memory processes due to
the chronic relapsing-remitting nature of SLE will determine
the cumulative corticosteroid exposure. The relationship
between corticosteroid use in acute disease and during mainte-
nance with corticosteroid dosage and cumulative dose is diffi-
cult to dissect. These probably interact in a complex manner
depending on disease activity, duration, type and number of
organ systems involved as well as accrued damage. Other
immunomodulatory medications such as hydroxychloroquine
and cyclophosphamide did not affect the patients’ cognitive
and memory functions [29]. Interestingly, a protective effect
of aspirin on memory function in SLE patients has been
reported [32].
Regarding the study limitations, firstly, the number of
patients included was low and it is noteworthy that the Wech-
sler Memory Tests took 1 h to be completed for each subject.
Secondly there was no MRI brain done for all subjects includ-
ing control. A negative history may not rule out neuropsychi-
atric lupus. Future longitudinal studies on a larger scale of
patients are recommended to explore these interesting results
and to include a wider population of healthy control to give
a better estimate of the impairment in SLE patients. Consider-
ing more parameters in a regression analysis and including
autoantibodies and SLE damage index would be more infor-
mative in future studies and help in detecting risk factors
and to provide a comprehensive picture of the cumulative dis-
ease damage especially with regard to subtle memory
dysfunction.
In conclusion there was a high prevalence of ‘overall’ mem-
ory dysfunction (46.7%) in our local SLE population. A cur-
rent low serum thyroxine level was found to be a risk factor
and this may be amenable to treatment. The cumulative dose
of corticosteroids and other immunomodulatory medications
were also not risk factors for ‘overall’ memory dysfunction.
However, the memory impaired patients performed signifi-
cantly poorer in 3 of the 4 memory sub-domains compared
with the non-impaired group. Impairment of the visual mem-
ory sub-domain was associated with SLE disease duration
whereas auditory memory dysfunction was associated with a
lower level of education.Conflict of interest
None.Acknowledgement
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